semaglutide supply news november 2025 The cash price for popular weight-loss medications Wegovy and and the medication authorized for people with type 2 diabetes Ozempic are dropping by 30% in U.S. on Monday, according to Novo Nordisk The push for Medicare to

However, your doctor will monitor for potential interactions and side effects

Helps support brighter, more radiant-looking skin with regular intake

Have some social strategies ready to go

Beer faces a different challenge: its larger serving sizes and carbonation can make it less comfortable for some users on these medications

Press | Mechanism: GLP-1 Novos amycretin enters Phase 3 recruitment in heart failure, standing up a roughly 900-site global trial Novo Nordisks amycretin (NNC0487-0111), its next-generation GLP-1/amylin dual agonist, moved its Phase 3 HF-POLARIS trial (NCT07567001) from not-yet-recruiting to recruiting this week, activating roughly 900 clinical sites across more than two dozen countries for a 5,610-patient study in people with obesity and heart failure